Newmark Arranges Sale of Burlington BioCenter in Suburban Boston

May 16, 2025 9:00 AM

Newmark is pleased to announce it has arranged the sale of Burlington BioCenter, a premier life science facility in Burlington, Massachusetts. The transaction was facilitated by Newmark Co-Head of U.S. Capital Markets Robert Griffin, along with Boston Capital Markets Executive Vice Chairman Edward Maher, Vice Chairman Matthew Pullen, Executive Managing Director James Tribble, Senior Managing Director Samantha Hallowell and Associate Director William Sleeper. The buyer is an owner-user that has chosen to remain unnamed.

Burlington BioCenter comprises 109,085 square feet across four stories and is one of the only fully built-out life science assets in the Burlington submarket. The property offers move-in-ready, best-in-class laboratory and office space, unlike most competing buildings in the area, which are delivered with shell space requiring significant tenant improvements.

“Burlington BioCenter stands alone in the Burlington submarket for its turnkey laboratory infrastructure and modern, full-floor buildouts,” said Pullen. “In a region where many life science buildings remain in shell condition, this asset is truly differentiated by its cutting-edge systems and immediate occupancy potential.”

Originally completed in 2019 with its interior laboratory buildouts finalized in 2022, the building features high-performance laboratory infrastructure, including pH neutralization, high-efficiency HVAC systems, backup power, dedicated loading and a freight elevator. Additional highlights include flexible floor plates with interconnecting staircases, a dramatic two-story lobby, floor-to-ceiling glass and premium finishes throughout.

Located at 4 Burlington Woods Drive, Burlington BioCenter offers excellent accessibility via Interstate 95/Route 128 and Route 3. It is positioned within a thriving suburban life science cluster supported by a strong labor pool, numerous amenities and proximity to top academic and research institutions.

Newmark Financial Analyst Grady Zink provided analytical support for the transaction.

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended March 31, 2025, Newmark generated revenues of over $2.8 billion. As of March 31, 2025, Newmark and its business partners together operated from 165 offices with approximately 8,100 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.